Mitochondrial membranes and associated apoptotic machinery

The mitochondrial membranes and associated apoptotic machinery constitute the primary regulatory site for the intrinsic pathway of apoptosis. This system is centered on the mitochondrial outer membrane (MOM), where the balance between pro-apoptotic (e.g., BAX, BAK) and anti-apoptotic (e.g., BCL-2, BCL-XL) members of the BCL-2 protein family determines cell fate [1, 2]. When pro-apoptotic signals predominate, MOM permeabilization (MOMP) occurs, resulting in the release of cytochrome c and other intermembrane space proteins into the cytoplasm [2]. These factors facilitate the assembly of the apoptosome and the subsequent activation of the caspase cascade, leading to organized cell destruction [1]. In many cancers, this machinery is hijacked through the upregulation of anti-apoptotic proteins, which prevents MOMP and confers resistance to chemotherapy [5]. Consequently, this system is a major therapeutic target, with drugs like venetoclax specifically inhibiting BCL-2 to induce apoptosis in malignant cells [3]. Additionally, the mitochondrial permeability transition pore (mPTP) within the inner membrane serves as a target for protecting cells against necrotic death in cardiovascular and neurodegenerative contexts [4].

Other names

Intrinsic apoptotic pathwayMitochondrial apoptotic pathwayMOMP machineryMitochondrial death machinery

The primary mechanism involves the modulation of mitochondrial outer membrane permeabilization (MOMP) through the inhibition of anti-apoptotic BCL-2 family proteins (e.g., BCL-2, BCL-XL, MCL-1) or the activation of pro-apoptotic members (e.g., BAX, BAK) [1, 2]. This leads to the release of cytochrome c and subsequent caspase activation [2]. Additionally, targeting the mitochondrial permeability transition pore (mPTP) can prevent mitochondrial dysfunction and necrotic cell death in ischemia-reperfusion injury [4].